Explore the revolutionary potential of biotechnology and gene editing, alongside crucial ethical considerations and ...
In biotech, the biggest delays and costs don’t come from science but from communication breakdowns between technical and ...
As instruments grow faster, leaders say clinical impact will depend on trust, standards, data, and assays built for real ...
Analysis of over 5,000 hours of clinical wear data validates Trinity Biotech’s CGM+ 's purpose-built capability to distinguish nocturnal compression-related false lows from true blood glucose lows - ...
Australian pharmaceutical and biotechnology start-ups are already looking to take their investments to jurisdictions ...
Congressional letters sent to the CEOs of Eli Lilly, Pfizer, Merck, BMS and AbbVie this week voicing concerns about the pharmas’ clinical trials in China highlight an ongoing discrepancy in how ...
Highlights Significant Clinical, Regulatory, and Strategic Progress, Supported by a Disciplined Capital Allocation Strategy ...
In its second acquisition of the week, Ipsen will take control of Memo Therapeutics and a first-in-class drug for BK ...
What do Botox, rat poison, weight-loss drugs and a fictional murder investigation have in common? At the University of Nevada ...
This latest patent builds directly on the Company’s previously issued U.S. Patent No. 12,350,242 and further strengthens its intellectual property protection around the MEAI (5-methoxy-2-aminoindane) ...
The FDA dealt Lantheus’ bid to garner approval of its radiodiopharmaceutical diagnostic kit a setback due to manufacturing issues at a third-party facility. (Stock Photo ) The FDA dealt Lantheus’ bid ...
During my recent participation in Geneva Science Diplomacy Week, organized by the Geneva Science and Diplomacy Anticipator (GESDA), I was reminded that one of the greatest challenges facing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results